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As ischemic stroke is associated with an excessive release of glutamate into the neuronal
extracellular space, a decrease in blood glutamate levels could provide a mechanism to remove it
from the brain tissue, by increasing the brain–blood gradient. In this regard, the ability of glutamate
oxaloacetate transaminase (GOT) to metabolize glutamate in blood could represent a potential
neuroprotective tool for ischemic stroke. This study aimed to determine the neuroprotective effects
of GOT in an animal model of cerebral ischemia by means of a middle cerebral arterial occlusion
(MCAO) following the Stroke Therapy Academic Industry Roundtable (STAIR) group guidelines. In
this animal model, oxaloacetate-mediated GOT activation inhibited the increase of blood and
cerebral glutamate after MCAO. This effect is reflected in a reduction of infarct size, smaller edema
volume, and lower sensorimotor deficits with respect to controls. Magnetic resonance spectroscopy
confirmed that the increase of glutamate levels in the brain parenchyma after MCAO is inhibited after
oxaloacetate-mediated GOT activation. These findings show the capacity of the GOT to remove
glutamate from the brain by means of blood glutamate degradation, and suggest the applicability of
this enzyme as an efficient and novel neuroprotective tool against ischemic stroke.
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Introduction
It is well established that during ischemia, glutamate
acts as an important mediator of neuronal degenera-
tion, being released in large amounts from neurons
and astrocytes, causing cellular overload of calcium,
mainly through its action on calcium-permeable
NMDA receptors. This overload of calcium leads to
necrosis and breakdown of cellular structures in-
cluding proteins, DNA, and membrane phospholi-
pids (Lipton, 1999). In fact, studies from our group
have demonstrated that neurologic deterioration of
patients with acute ischemic stroke is associated
with higher glutamate levels in blood and cerebrosp-
inal fluid (Castillo et al, 1996, 1997).
Under normal physiological conditions, glutamate
release in the synaptic cleft is quickly removed by
the excitatory amino-acid transporters (EAATs),
located on astrocytes and neurons (Hazell, 2007).
Apart from astrocytes and neurons, the presence of
EAATs has also been observed in endothelial cells
from the brain vasculature, showing an important
role of these cells in the maintenance of glutamate
levels in the extracellular medium (O’Kane et al,
1999). It has been described that endothelial cells
have facilitative carriers for glutamate in the luminal
membranes, and EAATs in the abluminal membrane.
This localization allows a unidirectional export of
glutamate from the brain to the blood torrent
following a gradient of concentration. Therefore,
the decrease of blood glutamate levels leads to a
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larger glutamate gradient between the brain and
blood, facilitating the lowering of extracellular levels
of brain glutamate (Gottlieb et al, 2003; Teichberg
et al, 2009).
As ischemic stroke is associated with an excessive
release of glutamate into the neuronal extracellular
space (Castillo et al, 1996, 1997), a decrease in the
levels of blood glutamate could provide a mechanism
to reduce extracellular glutamate at early times, with
possible therapeutic implications after an ischemic
insult (Gottlieb et al, 2003; Hawkins, 2009; O’Kane
et al, 1999; Teichberg et al, 2009).
In this regard, recent studies have reported that
glutamate oxaloacetate transaminase (GOT), a blood-
resident enzyme, can be used as an important
neuroprotective tool for brain diseases associated
with elevated levels of glutamate (Gottlieb et al,
2003; Teichberg et al, 2009; Zlotnik et al, 2007, 2008).
The potential applicability of GOT is based on the
fact that this enzyme, using oxaloacetate as cosub-
strate, is able to transform glutamate to 2-ketogluta-
rate and aspartate, leading to a decrease of glutamate
levels in the blood.
On the above premises, we aimed to demonstrate if
the reduction of glutamate levels in blood, by means
of oxaloacetate-mediated GOT activation, induces a




Experimental protocols were approved by the local Animal
Care Committee according to the European Union (EU)
rules (86/609/CEE, 2003/65/CE, and RD 1201/2005). Male
Sprague-Dawley rats (Harlan Laboratories, Udine, Italy)
with a weight of 300 to 330 g were used. Rats were watered
and fed ad libitum. Anesthesia was induced by inhalation
of 5% sevoflurane in a nitrous oxide/oxygen mixture (70/
30). Rectal temperature was maintained at 37.51C by using
a feedback-controlled heating pad. Glucose levels were
analyzed before surgery (ranging from 180 to 220 mg/dL).
Surgical Procedures
Transient focal ischemia was induced in rats by using the
occlusion of the middle cerebral artery (MCAO). Middle
cerebral arterial occlusion model of brain ischemia is
considered one of the best models to mimic human
ischemic stroke and has been used in numerous studies
in rats (Carmichael, 2005). Middle cerebral arterial occlu-
sion was performed as previously described (Longa et al,
1989) with some modification. In brief, under operating
microscope, the left common, external, and internal carotid
arteries were dissected from connective tissue through a
midline neck incision. The left external carotid artery and
pterygopalatine artery of the internal carotid artery were
separated and ligated by 5-0 silk sutures. A 23-mm segment
of 3-0 nylon monofilament suture with the tip rounded by
heat was inserted into the stump of the left common
carotid artery and advanced into the internal carotid artery
B19 to 20 mm from the bifurcation to occlude the origin of
the MCA. The suture was removed after 90 minutes of
occlusion. A laser-Doppler flow probe (tip diameter 1 mm)
attached to a flowmeter (PeriFlux 5000; Perimed AB,
Stockholm, Sweden) was located over the thinned skull
in the MCAO territory (4 mm lateral to bregma) to obtain a
continuous measure of relative cerebral brain flow during
the experiment. Only animals with a cerebral blood flow
reduction over 60% and with reperfusion after occlusion
were included in the study.
Animal Experimental Procedures
Experimental procedure was performed following five
criteria derived from the Stroke Therapy Academic
Industry Roundtable (STAIR) group guidelines for precli-
nical evaluation of stroke therapeutics (Philip et al, 2009):
(1) cerebral blood flow was measured to confirm the
vascular occlusion, as an index of the reliability of the
ischemic model; (2) animals were randomly assigned to
treatment groups of the study; (3) researchers were blinded
to treatment administration; (4) researchers were blinded
to treatments during outcome assessment; and (5) tem-
perature was controlled during the ischemic period.
Experimental Groups
Two experimental groups were designed: MCAO control
group (n = 10), treated with saline (0.9% of NaCl) intra-
venously given as a single-bolus injection, and MCAO-
treated group (n = 10), with oxaloacetate 3.5 mg/100 g
intravenously given as a single-bolus injection. Treatments
were administered in both the groups 90 minutes after
MCA occlusion (after ischemia). Oxalacetate solution (pH
adjusted to 7.4) was prepared in saline solution (0.9% of
NaCl) at a final concentration of 10 mg/mL; therefore,
the volume of bolus injected in the treated animals was
about 1 mL. A volume of 1 mL of saline was injected in
control animals.
In both experimental groups, glutamate blood levels,
infarct volumes, and edema development analysis were
performed. Furthermore, somatosensory tests were per-
formed on day 7. A sham group was also performed to
confirm that the surgery did not affect the analyzed
variables.
To study the effect of oxalacetate on blood glutamate and
aspartate levels in health animals, two doses of oxaloace-
tate were tested, 1.5 mg/100 g (intravenously) (n = 3) and
3.5 mg/100 g (intravenously) (n = 4).
Endothelial Cells Culture
Previous studies have established that the close proximity
of astrocytes is crucial to the development of endothelial
cells in culture models (Cohen-Kashi Malina et al, 2009),
therefore, an in vitro model based on a noncontact
coculture of rat endothelial cells with rat brain astrocytes
was chosen.
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In brief, initial primary astrocyte cultures were prepared
from neonatal (P0) Sprague-Dawley rat cortex, as pre-
viously described (McCarthy and de Vellis, 1980). For the
noncontact coculture, 105 astrocytes from the primary
culture were seeded on the bottom of poly-D-lysine (PDL)
coated six-well plates for 5 to 6 days in Dulbecco’s
modified Eagle growth medium supplemented with 10%
horse serum, 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (all from Gibco–Invitrogen Ltd, Paisley, UK). Then,
Dulbecco’s modified Eagle medium was removed and
7 104 rat endothelial cells (R840-05, Cell Applications
Inc, San Diego, CA, USA) were seeded on rat tail collagen
precoated (R35442, BD Biosciences, Madrid, Spain) trans-
well inserts in the six-well plate. Astrocytes and endothe-
lial cells were grown to confluence for 4 days in EGM MV
Microvascular Endothelial Cell Growth Medium (Lonza,
Basel, Switzerland).
Immunocytochemistry
To characterize the endothelial cells used, the specific cell
marker von Willebrand factor was used (Jaffe, 1977). For
this, 104 endothelial cells were grown onto culture slides
(R354632, BD Biosciences) for 4 days as previously
described. Then, cells were fixed with 4% paraformalde-
hyde in phosphate-buffered saline for 10 minutes and
subsequently permeabilized with 0.3% Triton X-100 for
5 minutes. After washing with Tris-buffered saline, they
were blocked with 5% bovine serum albumin in phos-
phate-buffered saline for 30 minutes. Cells were subse-
quently incubated with a polyclonal antibody raised in
rabbit against von Willebrand factor for 1 hour (1:400,
Abcam, Cambridge, UK), washed in Tris-buffered saline,
and incubated with an anti-rabbit tetramethylrhodamine
isothiocyanate (TRITC) conjugated for 1 hour (1:50, Invi-
trogen). Nuclei were counterstained by incubating with
Hoescht 33342 dye (2mg/mL, Molecular Probes-Invitrogen,
Paisley, UK) for 5 minutes and then washed in Tris-
buffered saline. All incubations were made at room
temperature. After mounting, slides were observed under
a fluorescence microscope (Olympus, Hamburg, Germany)
and images were acquired with a CCD camera (Nikon,
Nikon Precision Europe, Langen, Germany) using the NIS
Elements software.
Immunoblotting
Expression of tight junction proteins (Zonula occludens
protein-1 (ZO-1) and occludin) and glutamate transporters
(EAAT1, EAAT2, and EAAT3) were detected in the
endothelial cells by immunoblotting technique. At the
end of the culture period, endothelial cells grown on
transwell insert were rinsed with phosphate-buffered
saline and collected in ice-cold lysis buffer (Invitrogen)
with 1% antiprotease cocktail (Sigma-Aldrich Chemie
GMBh, Taufkirchen, Germany). A sample of brain cortex
(200 mg) from an adult health rat was also lysed to be used
as control. The different samples were sonicated for
15 seconds, boiled for 5 minutes, and cooled immediately
on ice. Sample extracts were centrifuged at 14,000 g for
5 minutes at 41C and supernatant protein concentration
was quantified using the Bradford method (Bio-Rad Protein
Assay Kit, Bio-Rad Laboratories Ltd, Herts, UK). Forty
micrograms of protein extract was subjected to sodium
dodecyl sulfate polyacrylamide gel electrophoresis on 8%
polyacrylamide gels. Gels were run at 20 mA for 90 min-
utes. Separated proteins were electroblotted onto poly-
vinylidene fluoride (PVDF) membranes at a constant
current intensity of 15 mA for 15 hours (semidry blotting).
Membranes were blocked for 60 minutes at room tempera-
ture in blocking buffer containing 5% nonfat dry milk and
then the blots were incubated overnight at 41C with the
primary antibody against the different proteins studied.
Primary antibodies used were rabbit polyclonal antibody
against ZO-1 (1:250, Invitrogen), mouse monoclonal anti-
body against occludine (1:500, Invitrogen), rabbit poly-
clonal antibody against EAAT1 (1:1000, Abcam), mouse
monoclonal antibody against EAAT2 (1:500, Abcam),
mouse monoclonal antibody against EAAT3 (1:500,
Abcam), and mouse monoclonal antibody against actin
(1:1000, Sigma). Actin was used as loading control. All
antibodies used were diluted in Tris-buffered saline-
Tween-bovine serum albumin (BSA) buffer (20 mmol/L
Tris base, 140 mmol/L NaCl, 0.1% Tween-20). After wash-
ing, the blots were incubated for 1 hour at room temperature
with the following secondary antibodies: goat anti-mouse
Cy3 (1:3000, GE Life Sciences, GE Healthcare Europe GmbH,
Munich, Germany) and goat anti-rabbit Cy5 (1:3000, GE Life
Sciences), according to the primary antibody used. Western
image was acquired with fluorescence scam (Molecular
Imager PharosFX Plus System, Bio-Rad).
Serum Glutamate and Aspartate Analysis
Glutamate and aspartate serum levels were determined by
high performance liquid chromatography analysis, follow-
ing a previously described method (White et al, 1986). The
experiments with oxalacetate administration with health
animals, glutamate and aspartate levels were measured
before the treatment (basal) and 1, 2, and 3 hours after the
treatment injection. In experiments with animal model of
ischemia, the blood samples were acquired before surgery
(basal sample) and 90 minutes (before treatment injection),
4 hours, 24 hours, 3 days, and 7 days after the occlusion.
Magnetic Resonance Imaging Protocol
Infarct size and edema extension were assessed by means
of magnetic resonance imaging. Magnetic resonance ima-
ging studies were conducted on a 9.4-T horizontal bore
magnet (Bruker BioSpin, Ettligen, Germany) with 20 cm
wide actively shielded gradient coils (440 mT/m). Radio-
frequency transmission was achieved with a birdcage
volume redsonator; signal was detected using a four-
element surface coil, positioned over the head of the
animal, which was fixed with a teeth bar, earplugs, and
adhesive tape. Transmission and reception coils were
actively decoupled from each other. Gradient-echo pilot
scans were performed at the beginning of each imaging
session for accurate positioning of the animal inside the
magnet bore. Apparent diffusion coefficient maps were
acquired using a spin-echo echo-planar imaging sequence
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with the following acquisition parameters: field-of-view
19.2 19.2 mm2, image matrix 128 128 (in-plane resolu-
tion 0.15 mm/pixel 0.15 mm/pixel), 14 consecutive slices
of 1 mm thickness, repetition time = 4 seconds, four seg-
ments, echo time = 30 ms, spectral bandwidth 2,50,000 Hz,
and seven diffusion b values: 0, 100, 300, 600, 800, 1000,
and 1400. T2-weighted images were acquired using a
multislice multiecho spin-echo sequence with the follow-
ing acquisition parameters: field-of-view 19.2 19.2 mm2,
image matrix 192 192 (isotropic in-plane resolution of
0.1 mm/pixel 0.1 mm/pixel), 14 consecutive slices of
1 mm thickness, repetition time = 3 seconds, and 16 echoes
with echo time = 9 ms. Diffusion-weighted images were
acquired immediately after removing the suture from the
animal (90 minutes after the occlusion). T2-weighted image
was acquired 24 hours, 3 days, and 7 days after the onset of
ischemia. All images were processed and maps were
constructed with ImageJ (Rasband WS, ImageJ, US National
Institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.
gov/ij/, 1997–2009).
In Vivo Magnetic Resonance Spectroscopy
Magnetic resonance spectra were acquired as previously
described (Higuchi et al, 1997; Tkac et al, 1999). Local
shimming was performed by manual adjustment of first-
and second-order shim coil currents using a Press-water-
line sequence. The field homogeneity in a 3-mm3 voxel
typically resulted in signal line widths of 11 to 20 Hz for
water. Water signal was suppressed by variable power RF
pulses with optimized relaxation delays. In vivo 1H
magnetic resonance spectra of the rat brain were acquired
by using a proton stimulated-echo acquisition mode
(STEAM-1H) sequence with echo time = 3 ms, mixing time
(TM) = 5 ms, repetition time = 2,500 ms, 176 averages, cubic
voxel = 3 3 3 mm3 (27 mL). Spectra were processed using
TOPSPIN 2.0 PV (Bruker BioSpin). For the quantitative
analysis, glutamate signals were normalized to creatine
peak areas for each single spectrum. Magnetic resonance
spectra were acquired during 1 hour before surgery, during
the occlusion (90 minutes), and during 4 hours after
reperfusion and treatment/saline injection. Middle cere-
bral arterial occlusion control group (n = 3) was treated
with saline and MCAO-treated group (n = 4) was treated
with oxaloacetate 3.5 mg/100 g, following the protocol
described previously.
Image Analysis
All images were processed using ImageJ (Rasband WS,
ImageJ, NIH, http://rsb.info.nih.gov/ij). Infarct volumes
were determined from quantitative diffusion and T2 maps
by manually selected areas of elevated apparent diffusion
coefficient/T2 values by a researcher blinded to animal
handling. Edema was estimated by measuring the volumes
of the affected (VLes) and contralateral (Vc) hemispheres
and using the formula: edema (%) = 100 (VLesVc)/Vc.
Somatosensory Test
Sensorimotor deficits were assessed as previously de-
scribed (Reglodi et al, 2003). All sensorimotor tests were
performed during the light cycle of animal housing, with
environmental conditions consistently maintained across
examinations. Briefly, the rodent’s walking pattern was
observed during a 1-minute period by a researcher blinded
to the animal grouping. A sensorimotor score on a scale of 0
to 3 was assigned to rats on the basis of their gait behavior.
0, Straight walking; 1, walking toward the contralateral
side; 2, alternate circling and walking straight; 3, circling
and/or other gait disturbance (backing, crawling, walking
on digits).
Statistical Analysis
Results are expressed as percentages for categorical vari-
ables and as mean (s.d.) or median (quartiles) for the
continuous variables, depending on the normal or not
normal distribution of data. Proportions were compared
using the w2 test, and the Student’s t-test or the Mann–
Whitney test to compare continuous variables between
groups. Spearman or Pearson analysis was used for
bivariate correlations.
Results
Characterization of Excitatory Amino-Acid
Transporters on Endothelial Cells
A noncontact coculture of rat endothelial cells with
rat brain astrocytes was chosen to check the expres-
sion of EAATs. This model allows the removal of
endothelial cells from the culture without contam-
ination from astrocytes (Figure 1A). Our cells were
positive for von Willebrand factor, a specific marker
for endothelial cells (Figure 1B). To check that
cultured endothelial cells had functional properties
close to those observed in vivo, the expression of
tight junction’s proteins was assessed by Western
blot analysis (Figure 1C). We used a sample of rat
brain as a positive control.
Once endothelial cells culture was characterized,
EAATs expression was analyzed. Figure 2 shows the
expression of EAAT1 and EAAT3 in endothelial
cells. We did not detect the presence of EAAT2 under
our experimental conditions. The expression of
EAAT1, EAAT2, and EAAT3 in a brain tissue sample,
used as positive control, confirmed that bands
observed in the Western blots effectively corre-
sponded to the analyzed proteins.
Effect of Oxaloacetate-Mediated Glutamate
Oxaloacetate Transaminase Activation on
Glutamate Blood Levels
A 1.5-mg/100 g dose of oxaloacetate was adminis-
tered by intravenous injection to healthy animals,
observing no changes on blood glutamate levels
within the first 3 hours after administration
(Figure 3A). As GOT metabolizes glutamate to
2-ketoglutarate and aspartate, we also analyzed
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aspartate levels on blood to confirm that the dose of
oxaloacetate used was not enough to activate GOT.
No changes on aspartate levels were observed (Figure
3B). When a higher dose of oxaloacetate of 3.5 mg/
100 g (intravenously) was used, a significant decrease
of glutamate levels was observed at 1 hour after
treatment, and maintained within the first 3 hours
after administration. The reduction of glutamate was
about 60% with respect to basal levels (P < 0.0001)
(Figure 3A). A concomitant increase on aspartate
levels (Figure 3B) seems to prove that the effect of
oxaloacetate on glutamate was actually mediated by
GOT activation (P < 0.0001). Glutamate and aspartate
blood levels were stable in control group treated with
saline (results not shown).
Neuroprotective Effect of Oxaloacetate-Mediated
Glutamate Oxaloacetate Transaminase Activation on
Middle Cerebral Arterial Occlusion Animal Models
Middle cerebral arterial occlusion induced an in-
crease of 40% on blood glutamate levels at 4 hours
after ischemia onset (Figure 4), which returned to
normal levels 24 hours later. The increasing effect of
cerebral ischemia on glutamate levels was inhibited
when oxaloacetate-mediated GOT activation (3.5 mg/
100 g) was induced (P < 0.0001).
To demonstrate that the reduction on blood
glutamate levels observed after GOT activation led
to a neuroprotective effect on our animal model of
cerebral ischemia, the infarct volumes of treated
versus control animals were compared. As shown in
Figures 5A and 5B, oxaloacetate-mediated GOT
activation decreased lesion sizes about 80%. At day
7, infarct volumes of treated group were significantly
lower than those for control group (P < 0.0001).
Diffusion-weighted images show that infarct vo-
lumes were similar for both experimental groups
before treatment. Regarding edema development,
control group showed higher edema than treated
animals (10% versus 2%, P < 0.0001) (Figure 5C).
Edema resolves at day 7 for all animals. This effect is
typical for this experimental model.
On the other hand, a lower sensorimotor deficit
was observed in treated animals compared with
controls (1 [1,2] versus 2 [2,3]; P = 0.011).
Magnetic Resonance Spectroscopic Analysis of
Cerebral Glutamate Levels in Middle Cerebral
Arterial Occlusion Animal Models
Magnetic resonance spectroscopic (Figures 6A
and 6B) analysis was used to study the time course
of cerebral glutamate levels in ischemic animals
treated with (3.5 mg/100 g) oxaloacetate and with
saline. Quantitative analysis of magnetic resonance
spectra revealed a persistent increase of glutamate
levels after the occlusion onset for control
group. Four hours after occlusion, the increase of
Figure 1 Coculture of astrocytes and endothelial cells used in the study. (A) Schematic drawing of the noncontact coculture of rat
endothelial cells with rat astrocytes. Astrocytes were grown on the top of the well and the endothelial cells in transwell. (B)
Immunocytochemistry of endothelial cells stained with von Willebrand factor. Nuclei were counterstained with Hoechst. (C) Western
blot analysis of the expression of occludin and ZO-1 proteins, in the endothelial cells (E), and rat brain cortex (C). Rat brain cortex
was used as positive control. ZO-1, Zonula occludens protein-1.
Figure 2 Excitatory amino-acid transporters (EAATs) protein
expresion in rat endothelial cells. Western blot analysis shows
the expression of EAAT1 and EAAT3, but not EAAT2, in
endothelial cells (E). Tissue from the brain cortex (C) was used
as positive control of EAATS.
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extracellular glutamate levels was about 300% with
respect to basal levels. A significant decrease of
glutamate levels in the brain parenchyma was
observed in the treated group with respect to the
control animals (P < 0.0001) (Figure 6C).
Discussion
The brain is an organ with a high content of
glutamate, the most important excitatory neurotrans-
mitter. Although its presence is essential for the
correct function of neuronal tissue, its excitatory
properties become dangerous for neurons when its
concentration in the extracellular fluid rises under
pathological conditions like ischemic stroke.
During ischemic stroke, glutamate is highly re-
leased to the extracellular space, mediating a marked
increase in intracellular calcium, followed by the
activation of intracellular enzymes, which provoke
neuronal death. The central role glutamate in the
ischemic cascade, make this neurotransmitter a good
target in the search for neuroprotective agents in
ischemic stroke.
In agreement with the previous findings (Zlotnik
et al, 2007, 2008), in the present manuscript, we
demonstrated that in ischemic stroke, a decrease in
blood glutamate levels by means GOT, provides a
neuroprotective mechanism to remove this neuro-
transmitter from the brain tissue to the blood through
the blood–brain barrier.
The expression of EAATs on brain capillary
endothelial cells has been described to be essential
for the diffusion of glutamate from the brain
parenchyma to blood. Prior to study the effects of
GOT and given that we used rats in our experiments,
the first step of our research was to demonstrate the
presence of EAATs on rat endothelial cells, where, to
the best of our knowledge, they have never been
described before. We focused our studies on EAAT1,
EAAT2, and EAAT3 due to their ubiquitous location
and because they have been previously described in
porcine and bovine brain endothelial cells (O’Kane
et al, 1999; Teichberg et al, 2009). We detected
EAAT1 and EAAT3, but not EAAT2 expression in rat
endothelial cells. The expression of at least two types
of EAATs on this cell type in rats seems to
demonstrate the permeability for glutamate from
the brain parenchyma into the blood torrent through
the blood–brain barrier.
A high number of neuroprotective agents found in
experimental research have failed in stroke clinical
trials, most of the cases due to the narrow therapeutic
window (Castellanos et al, 2006). Another important
reason has been the low quality and adequacy of
animal testing for neuroprotective agents for stroke
(Philip et al, 2009). For these reasons, oxaloacetate
was administered to demonstrate the properties of
Figure 3 Doses–reponse effect of oxaloacetate on blood
glutamate (A) and aspartate (B) levels. The treatment with
oxaloacetate 3.5 mg/100 g (intravenously) (n = 4) induces a
greater reduction in blood glutamate levels and increase in
aspartate than the dose of 1.5 mg/100 g (intravenously) (n = 3).
Glutamate and aspartate data are shown as mean±s.e.m. of
percentage with respect to basal levels (considered as 100%).
Figure 4 Time course of blood glutamate levels in control
(n = 10) and treated (n = 10) middle cerebral arterial occlusion
(MCAO) animals. The treatment with oxaloacetate 3.5 mg/100 g
(intravenously) induces a reduction in blood glutamate levels.
Glutamate levels are presented as mean±s.e.m.
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GOT activation as a neuroprotective tool within a
wide therapeutic window and following the STAIR
guidelines for preclinical evaluation of stroke ther-
apeutics (Philip et al, 2009). Besides, our primary
end point in the experimental study was infarct
volume. The infarct volume analysis represents an
objective and quantitative tool to estimate ischemic
brain injury and it is commonly used to determine
the efficacy of neuroprotective agents in preclinical
studies (Lin et al, 1993).
It has been described that GOT activation with
oxaloacetate 1.2 mg/100 g (intravenously) reduces
blood glutamate levels (Gottlieb et al, 2003; Nagy
et al, 2009). In disagreement with these results, we
observed no effects with a dose of 1.5 mg/100 g dose
within the first 4 hours after treatment under our
experimental conditions. However, when oxaloace-
tate 3.5 mg/100 g (intravenously) was tested, a sig-
nificantly maintained decrease on blood glutamate
levels was observed within the first hours. Therefore,
this last dose was chosen to test the neuroprotective
effect of oxaloacetate-mediated GOT activation.
The increase of blood glutamate levels observed
after MCAO disappeared when GOT was activated in
the treated group with oxaloacetate. This effect on the
reduction of blood glutamate levels was associated
with a decrease of infarct sizes and edema develop-
ment, as well as to a reduction on motor deficits.
Preclinical testing criteria for neuroprotective
agents establishes that they have to reduce the
ischemic damage at least by 50% or even better to
80% before being considered for clinical trials
(Fisher et al, 2007; Rother, 2008). Considering that
GOT activation reduces the ischemic damage about
80%, an optimal neuroprotective capacity is
expected for this enzyme.
High levels of glutamate in brain parenchyma
cause an overstimulation of AMPA and NMDA
receptors. Overstimulation of both receptors induces
an influx of calcium and sodium, leading to an
electrolytic disturbance in brain tissue and the
subsequent formation of cytotoxic edema. The
increase in tissue water content and brain swelling
that contribute to the ischemic injury worsen (Lin
et al, 1993; Moldes et al, 2008). Therefore, the
development of brain edema represents another good
marker to determine the neuroprotective efficacy of
GOT activation. In line with this, our results show
that oxaloacetate-mediated GOT activation reduced
the edema development.
It could be argued that observed effects could be
actually caused by neuroprotective properties of
Figure 5 Infarct size and edema development were assessed by means of magnetic resonance image (MRI). Diffusion-weighted
images (DWI) were acquired immediately after removing the suture from the animal (90 minutes after the occlusion); T2-weighted
(T2-W) images were acquired at 24 hours, 3 days, and 7 days after ischemia onset (A). (B) The time course of infarct volumes.
Treated middle cerebral arterial occlusion (MCAO) animals (n = 10) had smaller infarct volumes than control animals (n = 10). (C)
The time course of the edema volumes decreases in control and treated groups after MCAO. Edema volume decrease in the MCAO-
treated animals during the first 7 days. Infarct volumes (% of ipsilesional hemispheric volume) and edema (% ipsilesional versus
contralesional hemispheric volumes) are shown as mean±s.e.m.
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oxaloacetate and not to a real effect of GOT on brain
glutamate levels. To clarify this point, we performed
a magnetic resonance spectroscopy analysis of
glutamate levels in brain parenchyma. In agreement
with previous in vivo microdialysis studies (Berger
et al, 2008) and with the pathogenesis of ischemia
(Castillo et al, 1996, 1997) our in vivo spectroscopic
analysis showed an increase of glutamate levels in
the brain after MCAO, which is inhibited after
oxaloacetate-mediated GOT activation. These results
reinforce the proposed neuroprotective mechanism,
revealing the efficacy of GOT to remove brain
glutamate.
As it is shown in Figures 4 and 6, the decrease of
blood and brain glutamate levels takes place simul-
taneously after oxaloacetate treatment, reflecting a
rapid diffusion of glutamate from the brain into the
blood torrent. In this regard, kinetic studies by means
of radiolabeled glutamate injection into rat lateral
ventricles have also shown a fast (within 1 minute)
diffusion of glutamate from the brain parenchyma to
blood (Gottlieb et al, 2003). Therefore, the efficacy of
GOT to remove brain glutamate depends on its
ability to metabolize blood glutamate to increase
the concentration gradient between the brain par-
enchyma and blood torrent.
Although clinical studies are necessary to perform
and validate these results, in conclusion, the capa-
city of the GOT to remove glutamate from the brain
by means of blood glutamate degradation show that
this enzyme could be considered as an efficient and
novel neuroprotective tool against ischemic stroke.
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